RxDoctor Payments Data

Jack Uhrig, MD

Internal Medicine · Marshall, MONPI 1720024557

Payments from drug & device makers

$14,892in general payments, 2019–2025

Across 950 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • AbbVie$974
  • Medtronic$539
  • plus $6K from 45 others

What the payments were for

  • Food & beverage$14,77699%
  • Education$1161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,892 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$110,750
Medicare patients
812
Services billed
1,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban273$246,127
OzempicSemaglutide211$213,042
JardianceEmpagliflozin206$179,655
FarxigaDapagliflozin Propanediol143$100,033
Breztri AerosphereBudesonide/Glycopyr/Formoterol71$53,413
XareltoRivaroxaban55$52,456
MounjaroTirzepatide29$43,994
RybelsusSemaglutide40$40,174
EntrestoSacubitril/Valsartan32$30,971
TrulicityDulaglutide27$30,604
Oxtellar XrOxcarbazepine24$22,147
InvokanaCanagliflozin17$21,536
Potassium Chloride607$19,916
ArexvyRsvpref3 Antigen/As01e/Pf66$18,581
Metoprolol Succinate710$11,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,350$253,216251 claims
PfizerEliquis, Abrysvo$225$251,319291 claims
Boehringer IngelheimJardiance$448$179,655206 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$2,601$163,156238 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog Mix 75-25$1,396$79,07069 claims
Johnson & JohnsonXarelto, Invokana$486$73,99172 claims
NovartisEntresto$372$30,97132 claims
GSKArexvy, Trelegy Ellipta$57$26,99177 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Marshall

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →